Published in Alzheimers Res Ther on July 09, 2009
Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement (2010) 3.11
Early identification and heritability of mild cognitive impairment. Int J Epidemiol (2013) 1.83
Report of the task force on designing clinical trials in early (predementia) AD. Neurology (2010) 1.75
Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS One (2016) 1.38
Partial volume correction in quantitative amyloid imaging. Neuroimage (2014) 1.24
Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiol Aging (2010) 1.19
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology (2011) 1.06
Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative. Neurobiol Aging (2012) 1.02
Clinical trial methodologies for disease-modifying therapeutic approaches. Neurobiol Aging (2011) 0.95
For debate: substituting placebo controls in long-term Alzheimer's prevention trials. Alzheimers Res Ther (2011) 0.91
Role of HIV in amyloid metabolism. J Neuroimmune Pharmacol (2014) 0.90
Non-feminizing estrogens: a novel neuroprotective therapy. Mol Cell Endocrinol (2014) 0.81
Quantitative amyloid imaging using image-derived arterial input function. PLoS One (2015) 0.80
Therapeutics for cognitive aging. Ann N Y Acad Sci (2010) 0.79
Advances in quantitative magnetic resonance imaging-based biomarkers for Alzheimer disease. Alzheimers Res Ther (2010) 0.75
Partial volume correction for PET quantification and its impact on brain network in Alzheimer's disease. Sci Rep (2017) 0.75
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med (2005) 12.04
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 10.75
Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet (2008) 8.51
Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol (2008) 7.95
A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature (2001) 7.35
RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature (1996) 7.04
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature (2009) 6.99
Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol (2008) 4.07
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement (2007) 3.75
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med (2005) 3.46
The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta (2000) 3.33
Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol (1999) 3.20
Editorial: The prevalence and malignancy of Alzheimer disease. A major killer. Arch Neurol (1976) 2.62
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol (2008) 2.62
Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis (1996) 2.50
Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med (2006) 2.28
Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci (2007) 1.48
Clinical trials in mild cognitive impairment: lessons for the future. J Neurol Neurosurg Psychiatry (2005) 1.47
Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging (2006) 1.30
Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol (1998) 1.24
Hope in Alzheimer's fight emerges from unexpected places. Nat Med (2008) 1.20
A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology (2006) 1.14
GSK-3 inhibitors for Alzheimer's disease. Expert Rev Neurother (2007) 1.04
Use of structural imaging to study the progression of Alzheimer's disease. Br Med Bull (1996) 1.02
Longitudinal imaging in dementia. Br J Radiol (2007) 0.96
Current state of immunotherapy for Alzheimer's disease. CNS Spectr (2008) 0.96
Disease modifying trials in Alzheimer's disease: perspectives for the future. J Alzheimers Dis (2008) 0.79